Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Xevudy Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19 Dec 17, 2021 08:17AM
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19 Dec 17, 2021 08:16AM
Vir (VIR) and GlaxoSmithKline (GSK) Reports Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant Dec 7, 2021 04:10AM
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant Dec 7, 2021 03:48AM
Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Sotrovimab Retains Activity Against Key Omicron Mutations, per Preclinical Data Dec 2, 2021 05:49AM
View Older Stories

Dec 2, 2021 02:07AM Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
Nov 17, 2021 06:43AM GSK (GSK) and Vir Biotechnology (VIR) Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Nov 17, 2021 06:42AM GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Nov 12, 2021 07:13AM Vir Biotechnology Inc. (VIR) and GlaxoSmithKline (GSK) Phase 3 Trial of sotrovimab for Early Treatment of COVID-19 Met Primary Endpoint
Nov 12, 2021 07:10AM Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Nov 5, 2021 03:47PM GlaxoSmithKline (GSK) Reports Positive Phase 3 Efficacy and Safety Data for daprodustat
Nov 5, 2021 03:46PM GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
Jul 30, 2021 05:17AM GlaxoSmithKline (GSK) Announces FDA Approval of Nucala for Adults
Jul 29, 2021 06:03PM GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
Jul 16, 2021 08:15AM GSK anaemia drug shows promise as treatment in kidney disease patients
Jul 2, 2021 08:00AM Alector Inc. (ALEC) Partners with GlaxoSmithKline (GSK) to Study Treatments for Neurodegenerative Diseases
Jul 2, 2021 07:38AM Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
Jun 23, 2021 06:18AM GSK's drugs arm to get $11 billion booster from consumer spin-off
Jun 14, 2021 07:54AM GSK, iTeos to develop cancer drug in up to $2 billion deal
Jun 14, 2021 07:06AM iTeos Therapeutics (ITOS), GSK (GSK) announce pact for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
Jun 14, 2021 07:00AM iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
May 27, 2021 06:57AM GSK (GSK), Vir Biotechnology (VIR) Confirms FDA Emergency Use Authorization for COVID Treatment Sotrovimab
May 26, 2021 06:57PM GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Apr 22, 2021 04:33PM FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Mar 29, 2021 08:32AM Eli Lilly & Co. (LLY), Vir Biotech (VIR) & GlaxoSmithKline (GSK) Report Positive Topline Data from Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Mar 29, 2021 08:30AM Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Mar 29, 2021 08:30AM Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Mar 11, 2021 09:16AM Vir Biotechnology (VIR) Gains 50% as VIR-7831 Reduces Hospitalization and Risk of Death from COVID-19
Jan 27, 2021 06:45AM Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Jan 27, 2021 06:45AM Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Jan 12, 2021 06:19AM Vir Biotechnology Inc. (VIR), GlaxoSmithKline plc (GSK) Report NHS-Supported AGILE Study to Evaluate VIR-7832 in Early Treatment of COVID-19
Jan 12, 2021 03:00AM Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Dec 17, 2020 04:02PM Vir Biotechnology (VIR)and GSK (GSK) Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Dec 17, 2020 04:01PM Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Dec 17, 2020 08:59AM FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Oct 6, 2020 08:20AM Vir Biotechnology Inc. (VIR), GSK (GSK) announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for treatment of COVID-19
Oct 6, 2020 08:18AM Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Sep 25, 2020 03:58PM GlaxoSmithKline (GSK) Announces FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome
Sep 25, 2020 03:58PM FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)
Sep 9, 2020 06:45PM FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
Sep 9, 2020 06:24PM FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
Aug 31, 2020 08:01AM Vir Biotechnology Inc. (VIR), GlaxoSmithKline (GSK) Begin Phase 2/3 Study of COVID-19 Antibody Treatment
Aug 31, 2020 08:00AM Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
Aug 5, 2020 09:08PM FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Apr 29, 2020 05:03PM GlaxoSmithKline (GSK) announces FDA approves Zejula as once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer
Apr 29, 2020 04:13PM FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker
Apr 6, 2020 08:06AM Vir Biotechnology Inc. (VIR), GlaxoSmithKline (GSK) Enter Collaboration on Coronavirus; GSK to Make $250M Equity Investment at $37.73
Apr 6, 2020 08:01AM GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Dec 16, 2019 06:36PM Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Sep 28, 2019 10:31AM Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line p
Sep 12, 2019 03:50PM GlaxoSmithKline (GSK) announces FDA has approved Nucalafor use in children
Sep 12, 2019 03:48PM Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
Jun 6, 2019 05:15PM GlaxoSmithKline (GSK) Announces Nucala Gains FDA Approval for Two New Self-Administration Options
Jun 6, 2019 05:15PM Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options
May 2, 2019 12:22PM Innoviva (INVA), GlaxoSmithKline (GSK) Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint
View Older Stories